MAX-002

Phase 3Small molecule

FForest Laboratories

MAX-002 is one of 9 small molecule programs targeting Proctitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ProctitisActive, not recruiting

ProctitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Proctitis

#DrugCompanyPhaseTrials

Lialda

Takeda

Approved

—2

Prograf

VVeloxis Pharmaceuticals

Approved

1 3

Thalomid

Bristol-Myers Squibb

Phase 2

1 4

Pulmicort

SSalix

Phase 2

2 5

Restasis

TTaiwan Bio Therapeutics Inc.

Phase 2

1 6

Canasa

Novartis

Phase 3

1 7

MAX-002

FForest Laboratories

Phase 3

1 8

Mesenchymal Stem Cells

JJiangsu Topcel-KH Pharmaceutical Co., Ltd.

Phase 1

2 9

Mesalazine

Ferring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Proctitis1 trial

Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis

Terminated·FForest Laboratories·Phase 3·NCT01016262·119 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MAX-002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MAX-002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MAX-002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Forest Laboratories company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FForest Laboratories

MAX-002

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Proctitis1 trial

References

Drug Info

Quick Facts

Related News